BTSG

Over the past six months, BrightSpring Health Services' stock increased by 105.73% over 12 months and had a year-to-date return of 49.59% as of September 24, 2026, but decreased by 5.83% in the past month. On July 31, 2026, the stock declined 15.5% to 18% after Q2 2026 results, despite beating analyst expectations for EPS and revenue, and reporting strong growth in adjusted EBITDA (44.2%) and revenue (23%). The company also raised its full-year 2026 guidance, though management noted the Inflation Reduction Act created an approximate $50 million headwind in Q2 2026, impacting the Home and Community Pharmacy segment's revenue by 8.0%. More recently, as of October 7, 2026, the stock was on a 6-day winning streak, up 14.6%, adding about $1.7 billion to its market value, outperforming the S&P 500. Analysts maintain a 'Buy' consensus rating with a positive target price.